The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.

ABSTRACT:

Background

The inflammatory cascade is the main cause of death in COVID-19 patients. Corticosteroids (CS) and tocilizumab (TCZ) are available to treat this escalation but which patients to administer it remains undefined.

Objective

We aimed to evaluate the efficacy of immunosuppressive/anti-inflammatory therapy in COVID-19, based on the degree of inflammation.

Design

A retrospective cohort study with data on patients collected and followed up from March 1st, 2020, to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Patients under treatment with CS vs. those under CS plus TCZ were compared. Effectiveness was explored in 3 risk categories (low, intermediate, high) based on lymphocyte count, C-reactive protein (CRP), lactate dehydrogenase (LDH), ferriti

SUBMITTER: Rubio-Rivas M 

PROVIDER: S-EPMC8523009 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature